FIELD: medicine.
SUBSTANCE: invention relates to the use of pharmacologically active compounds for the treatment of neurodegenerative diseases in particular Alzheimer's disease. The invention relates to the use of 4-hydroxy-3,5-di-tert-butyl cinnamic acid (formula I) at a dose of 100 mg/kg orally in Alzheimer's disease as a cerebroprotective agent that regulates the function of VDAC1 channels.
EFFECT: invention provides effective treatment of Alzheimer's disease by using 4-hydroxy-3,5-di-tert-butyl cinnamic acid as a cerebroprotective agent that regulates the function of VDAC1 channels.
1 cl, 1 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TARGETED NON-INVASIVE TRANSPLANTATION INTO BRAIN OF FUNCTIONALLY ACTIVE MITOCHONDRIA FOR TREATING NEURODEGENERATIVE DISEASES | 2019 |
|
RU2744453C2 |
| CEREBROPROTECTOR OF METABOLIC ACTION AND THE METHOD FOR ITS PREPARATION | 2020 |
|
RU2761549C1 |
| 4-(3-((2-ADAMANTYL)AMINO)-3-OXOPROP-1-EN-1-YL)-N-HYDROXYBENZAMIDE - A NEW DRUG FOR THE TREATMENT OF ALZHEIMER'S DISEASE | 2022 |
|
RU2783995C1 |
| THERAPEUTIC COMPOSITIONS (U) | 1999 |
|
RU2242227C2 |
| METHOD OF TREATING ALZHEIMER'S DISEASE, PROGRESSIVE MULTIPLE SCLEROSIS, SEVERE STROKE, CEREBRAL AND BIRTH BRAIN INJURY, PARKINSONISM AND OTHER NEURODEGENERATIVE DISEASES | 2019 |
|
RU2737995C1 |
| USE OF A BENZOPYRAN DERIVATIVE FOR THE TREATMENT OF DEMENTIA OF ALZHEIMER'S TYPE ASSOCIATED WITH CALCIUM DYSREGULATION | 2023 |
|
RU2804398C1 |
| COMPOSITION FOR INCREASING EXPRESSION OF PGC-1Α | 2017 |
|
RU2814560C2 |
| METHOD FOR PREVENTING THE DEVELOPMENT OF MYOCARDIAL INFARCTION IN MICE WITH MELANOMA THAT DEVELOPED AGAINST THE BACKGROUND OF CHRONIC NEUROGENIC PAIN | 2022 |
|
RU2786322C1 |
| METHYLTHIONINIUM AS COGNITIVE ENHANCER | 2020 |
|
RU2824584C2 |
| AGENT WITH ANTIAPOPTOTIC ACTIVITY | 2018 |
|
RU2685428C1 |
